Covid-19 vaccines: adverse events following immunisation

Patients rely on healthcare providers as their most credible and frequent source of vaccine information. It is therefore crucial that healthcare providers are informed and have evidence-based, objective and clear guidance on vaccine efficacy and specific adverse events following immunisation (AEFI)....

Full description

Saved in:
Bibliographic Details
Published inCurrent allergy & clinical immunology Vol. 35; no. 1; pp. 16 - 22
Main Authors Van den Berg, Sylvia, Van Rooyen, Cathy, Wessels, Pieter F, Brauer, Marieke, Green, Robin J
Format Journal Article
LanguageEnglish
Published Allergy Society of South Africa (ALLSA) 01.03.2022
Subjects
acute transverse myelitis (ATM)
Adverse events
Cardiac complications
cardiomyopathy
Covid-19 vaccine
Guillain-Barré syndrome (GBS)
Myocarditis
Pericarditis
Skin rash
Thrombosis
urticarial
vaccine allergy
Online AccessGet full text

Cover

More Information
Summary:Patients rely on healthcare providers as their most credible and frequent source of vaccine information. It is therefore crucial that healthcare providers are informed and have evidence-based, objective and clear guidance on vaccine efficacy and specific adverse events following immunisation (AEFI). Reported serious AEFIs are extremely rare for the COVID-19 vaccines. This article discusses the main AEFIs attributed to COVID-19 vaccines, including neurological complications of Guillain-Barré syndrome (GBS) and acute transverse myelitis (ATM), thrombosis; cardiac complications, including myocarditis, pericarditis and cardiomyopathy; and allergic reactions such as anaphylaxis, urticaria and skin rashes. The benefits of COVID-19 vaccination outweigh the risks; however, it is important that healthcare providers are aware of the risks and know how to recognise and manage them.
ISSN:1609-3607
DOI:10.10520/ejc-caci-v35-n1-a3